Abstract
Amino acid derived polypeptides are often biocompatible, and hence the materials of choice in nanoparticle formulations to avoid nanotoxicity and associated complications. A hydrophilic linear polypeptide γ-poly(l-glutamic acid) can form self-assembled nanoparticles only when made amphiphilic by chemical modification. Present work investigated pharmaceutical feasibility of a newly synthesized l-glutamic acid-based dendritic lipopeptide oligomer, which was found to be biocompatible and devoid of any inherent anticancer activity in vitro. Gefitinib, a poorly water-soluble anticancer drug, was used as the model drug to prepare an oligomeric nanosuspension by solvent evaporation–ultrasonication method. The formulation was optimized using response surface methodology and Box–Behnken model of design of experiments. The optimized gefitinib-loaded oligomeric nanosuspension demonstrated acceptable particle-size distribution, surface morphology, colloidal stability, entrapment efficiency, and drug release profile. Overall, current work highlights competence of a newly synthesized dendritic lipopeptide oligomer for drug delivery applications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahire E, Thakkar S, Darshanwad M, Misra M (2018) Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications. Acta Pharm Sin B 8(5):733–755. https://doi.org/10.1016/j.apsb.2018.07.011
Ameeduzzafar QM, Alruwaili NK (2020) BBD-based development of itraconazole loaded nanostructured lipid carrier for topical delivery: in vitro evaluation and antimicrobial assessment. J Pharm Innov. https://doi.org/10.1007/s12247-019-09420-5
Banik BL, Fattahi P, Brown JL (2016) Polymeric nanoparticles: the future of nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8(2):271–299. https://doi.org/10.1002/wnan.1364
Bolhassani A, Javanzad S, Saleh T, Hashemi M, Aghasadeghi MR, Sadat SM (2014) Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother 10(2):321–332. https://doi.org/10.4161/hv.26796
Chadha R, Bhandari S (2014) Drug-excipient compatibility screening—role of thermoanalytical and spectroscopic techniques. J Pharm Biomed 87:82–97. https://doi.org/10.1016/j.jpba.2013.06.016
Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC (2010) Polymeric nanoparticles for drug delivery. Methods Mol Biol 624:163–175. https://doi.org/10.1007/978-1-60761-609-2_11
Daneshmand S, Golmohammadzadeh S, Jaafari MR et al (2018) Encapsulation challenges, the substantial issue in solid lipid nanoparticles characterization. J Cell Biochem 119(6):4251–4264. https://doi.org/10.1002/jcb.26617
DeLuca PP, D’Souza SS (2006) Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm Res 23(3):460–474. https://doi.org/10.1007/s11095-005-9397-8
Dhillon S (2015) Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. Target Oncol 10(1):153–170. https://doi.org/10.1007/s11523-015-0358-9
European Medicines Agency (2009) Opaxio: withdrawal of the marketing authorisation application. EMA Europe. https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/opaxio. Accessed 25 May 2020
Gupta M, Marwaha RK, Dureja H (2017) Development and characterization of gefitinib loaded polymeric nanoparticles by ionic gelation method. Pharm Nanotechnol 5(4):301–309. https://doi.org/10.2174/2211738505666171004124109
Gupta M, Marwaha RK, Dureja H (2019) Formulation and characterization of gefitinib-loaded polymeric nanoparticles using Box-Behnken design. Curr Nanomed 9(1):46–60. https://doi.org/10.2174/2468187308666180815145350
Hegde N, Velingkar V, Prabhakar B (2019) An update on design and pharmacology of dendritic poly(l-lysine). Int J Pept Res Ther 25:1539–1562. https://doi.org/10.1007/s10989-018-9798-2
Hegde N, Juvale K, Prabhakar B (2020a) Synthesis and in vitro evaluation of inherent properties of l-glutamic acid based dendritic lipopeptide oligomers. J Pharm Innov. https://doi.org/10.1007/s12247-020-09493-7
Hegde N, Juvale K, Prabhakar B (2020b) Synthesis, characterization and biological evaluation of lipopeptide oligomer: a novel pharmaceutical excipient. Proceedings of International Conference on Drug Discovery (ICDD) 2020, SSRN 3533751, Schrodinger Inc. and Birla Institute of Technology and Science, Hyderabad.
Hegde N, Juvale K, Prabhakar B (2020c) p-Toluenesulfonyl chloride catalysed facile synthesis of O-benzyl-l-amino acids and their in vitro evaluation. Int J Pept Res Ther. https://doi.org/10.1007/s10989-019-09998-x
Jacob S, Nair AB, Shah J (2020) Emerging role of nanosuspensions in drug delivery systems. Biomater Res 24:3. https://doi.org/10.1186/s40824-020-0184-8
Juvale K, Stefan K, Wiese M (2013) Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. Eur J Med Chem 67:115–126. https://doi.org/10.1016/j.ejmech.2013.06.035
Khalil IR, Burns AT, Radecka I et al (2017) Bacterial-derived polymer poly-γ-glutamic acid (γ-PGA)-based micro/nanoparticles as a delivery system for antimicrobials and other biomedical applications. Int J Mol Sci 18(2):313. https://doi.org/10.3390/ijms18020313
Mahesh S, Tang KC, Raj M (2018) Amide bond activation of biological molecules. Molecules 23(10):2615. https://doi.org/10.3390/molecules23102615
Pani NR, Nath LK, Acharya S, Bhuniya B (2012) Application of DSC, IST, and FTIR study in the compatibility testing of nateglinide with different pharmaceutical excipients. J Therm Anal Calorim 108:219–226. https://doi.org/10.1007/s10973-011-1299-x
Parhi R, Panchamukhi T (2020) RSM-based design and optimization of transdermal film of ondansetron HCl. J Pharm Innov 15:94–109. https://doi.org/10.1007/s12247-019-09373-9
Pramod K, Suneesh CV, Shanavas S, Ansari SH, Ali J (2015) Unveiling the compatibility of eugenol with formulation excipients by systematic drug-excipient compatibility studies. J Anal Sci Technol 6:34. https://doi.org/10.1186/s40543-015-0073-2
Rahman AF, Korashy HM, Kassem MG (2014) Gefitinib. In: Brittain H (ed.) Profiles of drug substances, excipients, and related methodology, vol. 39 1st edn. Elsevier, pp 239–264. doi: https://doi.org/10.1016/B978-0-12-800173-8.00005-2
Sahu BP, Das MK (2014) Nanosuspension for enhancement of oral bioavailability of felodipine. Appl Nanosci 4:189–197. https://doi.org/10.1007/s13204-012-0188-3
Varma MM, Pandi JK (2005) Dissolution, solubility, XRD, and DSC studies on flurbiprofen-nicotinamide solid dispersions. Drug Dev Ind Pharm 31(4–5):417–423. https://doi.org/10.1080/03639040500214613
Wang Y, Li P, Truong-Dinh Tran T, Zhang J, Kong L (2016) Manufacturing techniques and surface engineering of polymer based nanoparticles for targeted drug delivery to cancer. Nanomaterials (Basel) 6(2):26. https://doi.org/10.3390/nano6020026
Zhang H, Li Q, Zhu X (2018) Association of variability and pharmacogenomics with bioequivalence of gefitinib in healthy male subjects. Front Pharmacol 9:849. https://doi.org/10.3389/fphar.2018.00849
Acknowledgements
Authors are thankful to the institute Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM’s NMIMS University for providing comprehensive research facilities. The authors also thank Mr. Sachin Puri for extending help in performing the cell line studies. The authors are grateful to Hetero Labs Ltd, Telangana, India for providing gefitinib as a generous gift sample.
Funding
Not applicable.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
Authors do not have any conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hegde, N., Juvale, K. & Prabhakar, B. Formulation and optimization of gefitinib-loaded nanosuspension prepared using a newly developed dendritic lipopeptide oligomer material. Chem. Pap. 75, 2007–2022 (2021). https://doi.org/10.1007/s11696-020-01453-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11696-020-01453-2